Singapore, Sept. 11 -- Viral Vector Manufacturing Facility (VVMF), Australia's first viral vector Contract Development and Manufacturing Organisation (CDMO) has announced that the Therapeutic Goods Administration (TGA) has granted the company a License to Manufacture Therapeutic Goods (GMP licence) for the Sydney facility.

This milestone is significant for Australia's rapidly growing cell and gene therapy sector, enabling VVMF to manufacture viral vectors under GMP conditions to support the development and commercialisation of advanced therapeutic products for Australian and Global clients.

The license authorises the GMP manufacture of replication-incompetent viral vectors using recombinant technology, as either sterile Active Pharmaceu...